Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Guided Therapeutics (GTHP) over the last 13 years, with Q3 2025 value amounting to $2000.0.

  • Guided Therapeutics' Depreciation & Amortization (CF) changed 0.0% to $2000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $9000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $9000.0 for FY2024, which is 0.0% changed from last year.
  • Per Guided Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $2000.0 for Q3 2025, which was down 0.0% from $3000.0 recorded in Q2 2025.
  • Over the past 5 years, Guided Therapeutics' Depreciation & Amortization (CF) peaked at $2.3 million during Q3 2023, and registered a low of $1000.0 during Q3 2022.
  • Moreover, its 4-year median value for Depreciation & Amortization (CF) was $2000.0 (2023), whereas its average is $180230.8.
  • Per our database at Business Quant, Guided Therapeutics' Depreciation & Amortization (CF) skyrocketed by 23150000.0% in 2023 and then tumbled by 9991.36% in 2024.
  • Quarter analysis of 4 years shows Guided Therapeutics' Depreciation & Amortization (CF) stood at $3000.0 in 2022, then crashed by 33.33% to $2000.0 in 2023, then changed by 0.0% to $2000.0 in 2024, then changed by 0.0% to $2000.0 in 2025.
  • Its last three reported values are $2000.0 in Q3 2025, $3000.0 for Q2 2025, and $2000.0 during Q1 2025.